Moksha8 Pharmaceuticals, Inc.
Location
Pennsylvania
Founded
2006-03-24
Risk Signals
9 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Moksha8 Pharmaceuticals, Inc.
Live alerts from global media, monitored by Business Radar
(koreabiomed.com)
Daewoong secures landmark BTX export deal in Latin America < Pharma < Article -
Daewoong Pharmaceutical has signed a 180 billion won ($125 million) botulinum toxin (BTX) export contract with M8 Pharmaceuticals, its partner in Brazil, marking its largest deal in Latin America since entering the market. The five-year agreement, announced Friday, is 10 times the size of Daewoong's
Read more
(medicaldevice-network.com)
M8 to market Futura's erectile dysfunction gel in more countries - Medical Device Network
M8, already with rights to supply Eroxon in Mexico and Brazil, has expanded its licensing agreement with Futura to 14 further countries.
Read more
(prnewswire.com)
M8 Pharmaceuticals obtains market authorization for Barlo® (Carragelose®) nasal spray in Mexico
/PRNewswire/ -- M8 pharmaceuticals is pleased to announce the market approval of a Barlo® (Carragelose®) nasal spray in Mexico. In 2021, Marinomed announced a...
Read more